FEATURED EDITORIAL
The central and peripheral nervous systems and the immune system are interconnected, working together to maintain tissue homeostasis and respond to environmental challenges.
- Autoimmune Drugs For Women: What To Bring To The Clinic
- Datapoints Summit 2026 Highlights: Moving AI Closer To The Lab
- Can An Ibogaine Analog Preserve The Therapeutic Potential Without The Trip Or Cardiac Risk?
- Viewing Treatment Resistance As A Target
- Wall Street Is Wary Of NAMs — And For Good Reason: What Happens To Yesterday's Drugs?
- What I Heard When NAMs Became a Conversation, Not a Webinar
- Using Low-Intensity Focused Ultrasound To Open The Blood–Brain Barrier
FEATURED APPLICATION CONTENT
-
Uncover how EPR spectroscopy fills the conformational gap by capturing dynamic protein motions, refining Cryo-EM models, and revealing hidden structural ensembles for drug discovery.
-
Growing demand for cell and gene therapies is increasing pressure on cytokine production. Explore interleukin manufacturing, quality, consistency, safety, scalability, and supply reliability.
-
Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.
-
See how expression hosts affect recombinant EPO glycosylation, bioactivity, and consistency, with reproducible N-glycan profiles and absence of α1,3-linked fucosylation.
-
Explore how D. mel-derived human prolactin (hPRL) compares with hPRL expressed in E. coli and HEK293 cells through detailed physico-chemical and biological characterization.
-
SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.
-
A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.
-
Antibody-oligonucleotide conjugates introduce conjugation and purification challenges that standard ADC process development wasn't designed to solve. This white paper details practical approaches for each.
-
Discover how automated EPR pulsed dipolar spectroscopy measures protein dynamics, complements Cryo-EM and AlphaFold, and delivers crucial structural insights for drug discovery.
-
Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
- Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics
- Bravo, FDA For Retiring 'Animal Testing' In Favor Of 'Nonclinical'
- Datapoints Summit 2026 Highlights: Moving AI Closer To The Lab
- What I Heard When NAMs Became a Conversation, Not a Webinar
- A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Breaking The Safety Barrier: Insilico Medicine Nominates ISM1354, The Next-Generation Small Molecule GIPR Antagonist
- Tremont AI Emerges From Stealth To Bring Multimodal AI To Preclinical Drug Safety
- Corbus Pharmaceuticals Announces First Patient Dosed In TEMPO-1 Registrational Study Of CRB-701 In Patients With 2L+ Oropharyngeal Cancer
- BRC Therapeutics Joins FDA And EMA Regulators At Workshop Advancing The Future Of Botanical Drug Development
- Lupin Receives Tentative Approval From U.S. FDA For Novel Apixaban Oral Suspension
- Bruker Advances Functional Proteomics With Novel timsUltra AIP And timsOmni Workflows For Drug Discovery & Development And Disease Biology Research
- Mission Bio Showcases Tapestri Across Drug Discovery And Clinical Development At World CDx Summit
- Future Fields Closes Oversubscribed $8M Series A to Turn Flies Into Bioreactors That Address Undruggable Diseases
- Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance
- Earendil Labs Announces Research Collaboration With Genentech To Discover And Develop Therapeutic Bispecific Antibodies In Oncology
ARCHIVED NEWSLETTER
- 09.29.26 -- What I Heard When NAMs Became A Conversation, Not A Webinar
- 09.22.26 -- 2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics
- 09.16.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises
- 09.15.26 -- A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials
- 09.10.26 -- Advance Drug Development With Analytical Characterization Solutions
